WO1997002350B1 - Recombinant human prostate specific antigen and uses thereof - Google Patents

Recombinant human prostate specific antigen and uses thereof

Info

Publication number
WO1997002350B1
WO1997002350B1 PCT/EP1996/002779 EP9602779W WO9702350B1 WO 1997002350 B1 WO1997002350 B1 WO 1997002350B1 EP 9602779 W EP9602779 W EP 9602779W WO 9702350 B1 WO9702350 B1 WO 9702350B1
Authority
WO
WIPO (PCT)
Prior art keywords
hpsa
recombinant
column
specific antigen
arg
Prior art date
Application number
PCT/EP1996/002779
Other languages
French (fr)
Other versions
WO1997002350A1 (en
Filing date
Publication date
Priority claimed from FI953257A external-priority patent/FI953257A/en
Application filed filed Critical
Priority to US08/973,719 priority Critical patent/US6140468A/en
Priority to EP96923930A priority patent/EP0835317A1/en
Priority to JP9504778A priority patent/JPH11508449A/en
Publication of WO1997002350A1 publication Critical patent/WO1997002350A1/en
Publication of WO1997002350B1 publication Critical patent/WO1997002350B1/en

Links

Abstract

The present invention relates to the production and purification of human prostate specific antigen (hPSA) by recombinant-DNA-technology. hPSA was produced in an active and an inactive form by the baculovirus expression vector system. Recombinant protein was secreted into the culture medium at a high yield by infected insect cells and purified to homogeneity by three-step procedure containing cation-exchange chromatography and gel filtration. The active protein obtained differs from the native protein in that it is unglycosylated and that it does not degrade the kallikrein-specific substrate H-D-Pro-Phe-Arg-pNA.HC1. The inactive form of hPSA obtained has two additional amino acid residues in its N-terminus, and it does not form complexes. Possible uses of the recombinant protein are also disclosed.

Claims

24AMENDED CLAIMS[received by the International Bureau on 14 January 1997 (14.01.97); original claims 1 and 8 cancelled; remaining claims amended and renumbered as claims 1-6 (2 pages)]
1. Recombinant human prostate specific antigen (hPSA) which is characterized in that
a) it is obtainable by recombinant-DNA-technology using baculovirus expression system in infected insect cells, b) it has the following N-terminal amino acid sequence: Ser-Arg-Ile-Val-Gly-Gly- Trp-Glu-Cys-Glu-Lys-His-Ser, c) it does not form complexes with αrantichymo trypsin or α2-macroglobulin, d) it has no activity on the substrates MeO-Suc-Arg-Pro-Tyr-pNAΗCl and H-D- Pro-Phe-Arg-pNA • 2HC1.
2. Process for the production ofthe recombinant hPSA of claim 1, comprising
a) incoφorating the cDNA encoding hPSA into a transfer vector, b) cotransfecting said vector with baculovirus-DNA into Spodoptera frugiperda cells, c) cultivating said cells in a suitable insect cell cultivation medium, d) harvesting the culture medium, and e) purifying the hPSA secreted into the culture medium.
3. Process according to claim 2 wherein the purification of step e) is effected by - dialyzing the culture medium, loading the dialysate onto a fluidized bed column having strong cation-exchange matrix, eluting the hPSA from the column by salt gradient, concentrating the hPSA fragments, - gel filtrating the concentrate obtained, dialyzing the hPSA fractions eluted from the gel filtration column, loading the dialyzate onto a cation-exchange chromatography column, and eluting the active and inactive pools of recombinant hPSA from the column with a linear salt gradient.
4. In a method for immunometric assay of human prostate specific antigen (hPSA) in human body fluids, an improvement comprising use ofthe hPSA according to claim 1 as a standard protein.
5. The improvement according to claim 4 wherein the body fluid is serum.
6. Use of the hPSA protein according to claim 1 as a standard protein in immunometric hPSA assays.
PCT/EP1996/002779 1995-06-30 1996-06-26 Recombinant human prostate specific antigen and uses thereof WO1997002350A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08/973,719 US6140468A (en) 1995-06-30 1996-06-26 Recombinant human prostate specific antigen
EP96923930A EP0835317A1 (en) 1995-06-30 1996-06-26 Recombinant human prostate specific antigen and uses thereof
JP9504778A JPH11508449A (en) 1995-06-30 1996-06-26 Recombinant human prostate specific antigen and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI953257A FI953257A (en) 1995-06-30 1995-06-30 Recombinant human prostate-specific antigen and its uses
FI953257 1995-06-30

Publications (2)

Publication Number Publication Date
WO1997002350A1 WO1997002350A1 (en) 1997-01-23
WO1997002350B1 true WO1997002350B1 (en) 1997-02-13

Family

ID=8543716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002779 WO1997002350A1 (en) 1995-06-30 1996-06-26 Recombinant human prostate specific antigen and uses thereof

Country Status (5)

Country Link
US (1) US6140468A (en)
EP (1) EP0835317A1 (en)
JP (1) JPH11508449A (en)
FI (1) FI953257A (en)
WO (1) WO1997002350A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
DE19916242C2 (en) * 1999-04-10 2003-04-10 Seratec Ges Fuer Biotechnologi PSA-containing substance and its use
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
CN117233413A (en) 2019-08-05 2023-12-15 禧尔公司 Systems and methods for sample preparation, data generation, and protein crown analysis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941645B (en) * 1994-03-09 1995-01-13 South To South Co Operation In Antibodies specifically reactive against human prostate specific antigen.
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator

Similar Documents

Publication Publication Date Title
EP0460882B1 (en) Lipopeptide deacylase
US4355104A (en) Bacteriolytic proteins
EP0509553A1 (en) Anti-lymphotoxin antibody, its production and use
JP2007084554A (en) New protein and method for producing medicine by using the same
CA2144056A1 (en) Cd27 ligand
JPS62223197A (en) Purification of alpha-1-anti-protease
JPH0822240B2 (en) Method for removing N-terminal amino acid residues from eukaryotic polypeptide analogs and polypeptides produced thereby
EP0204527A1 (en) Removal of the N-terminal methionine from methionylproteins
US5484887A (en) Homogeneous interleukin 1
WO1997002350B1 (en) Recombinant human prostate specific antigen and uses thereof
US20030190732A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
EP0587541A1 (en) Process to purify the big-endothelin protein
Butler et al. Homologous regions of collagen α1 (I) and α1 (II) chains: Apparent clustering of variable and invariant amino acid residues
EP0816504B1 (en) Platelet activating factor acetylhdrolase, and gene thereof
EP0480048A1 (en) Process for purifying polypeptide
US5573923A (en) Method for removing N-terminal dipeptides from precursor polypeptides with immobilized dipeptidylaminopeptidase from dictyostelium discoideum
KR940009329A (en) Dictiostelium Dipeptidylaminopeptidase
CA2008824C (en) Method for the production of glucagon
US6218517B1 (en) Protein having a vascularization inhibitory effect and a method for production thereof and a method for producing angiostatin
RU2223315C2 (en) RECOMBINANT ACTIVATOR OF DESMONDUS ROTUNDUS SALIVA α1-PLASMINOGEN (RDSPA α1), METHOD FOR ITS PURIFICATION, PHARMACEUTICAL COMPOSITION BASED ON THEREOF
AU603609B2 (en) Protein purification
Lu et al. Isolation and Characterization of Human Tissue Kallikrein Produced inEscherichia coli: Biochemical Comparison to the Enzymatically Inactive Prokallikrein and Methionyl Kallikrein
EP0244147A2 (en) Purification process for hybrid proteins
US4526782A (en) Process for recovering interferon
Takeuchi et al. Purification of human lung angiotensin-converting enzyme by high-performance liquid chromatography: Properties and N-terminal amino acid sequence